Rocket Pharmaceuticals
The Empire State Building
350 Fifth Ave, Suite 7530
New York
New York
10118
United States
Tel: 646-440-9100
Fax: 646-224-9585
Website: https://www.rocketpharma.com/
Email: info@rocketpharma.com
140 articles with Rocket Pharmaceuticals
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/19/2022
Rocket Pharmaceuticals, Inc. announces positive top-line safety and efficacy data from its Phase 2 pivotal trial for severe Leukocyte Adhesion Deficiency-I at the 25th Annual Meeting of the American Society of Gene and Cell Therapy.
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/16/2022
Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 2 pivotal trial for Fanconi Anemia and Phase 1 trials for Danon Disease and Pyruvate Kinase Deficiency at the 25th Annual Meeting of the American Society of Gene and Cell Therapy.
-
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
5/11/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation at the UBS Global Healthcare Conference on Tuesday, May 24 at 7:45 a.m. ET, in New York.
-
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
5/5/2022
Rocket Pharmaceuticals, Inc. reports financial results for the quarter ending March 31, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
4/27/2022
Rocket Pharmaceuticals, Inc . today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver an in-person company presentation at the Bank of America Securities Healthcare Conference on Wednesday, May 11 at 2:20 p.m. ET.
-
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
3/29/2022
Rocket Pharmaceuticals, Inc. today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver a virtual company presentation at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on Friday, April 1 at 8:00 a.m. ET.
-
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
3/14/2022
Rocket Pharmaceuticals, Inc. today announces the appointment of Fady Malik, M.D., Ph.D., to its Board of Directors.
-
Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
3/8/2022
Rocket Pharmaceuticals, Inc. today announces the appointment of Jessie Yeung as Vice President of Investor Relations and Corporate Finance.
-
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
2/24/2022
Rocket Pharmaceuticals, Inc. today reports financial and operational results for the fourth quarter and year ended December 31, 2021.
-
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Rocket Pharmaceuticals, Inc. announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET.
-
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
1/11/2022
Rocket Pharmaceuticals, Inc. today shares expected milestones for 2022, which were discussed yesterday during the Company’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
12/13/2021
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), today announces positive clinical updates from its ongoing Phase 2 registrational trials for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) and its ongoing Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the 63rd American Society of Hematology (ASH) Annual Meeting.
-
Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer
12/8/2021
Rocket Pharmaceuticals, Inc. today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President.
-
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
11/15/2021
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
-
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
11/11/2021
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data